<DOC>
	<DOCNO>NCT02106247</DOCNO>
	<brief_summary>To assess reduction ß-amyloid level cerebrospinal fluid plasma evaluate pharmacokinetics , safety tolerability follow single oral dos BI 1181181 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Oral Doses BI 1181181 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male accord investigator´s assessment , base follow criterion : complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 2 . Age 18 50 year ( incl . ) 3 . BMI 18.5 29.9 kg/m2 ( incl . ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator 2 . Repeated measurement systolic blood pressure &lt; 90 mmHg &gt; = 140 mmHg screen supine position 3 . Repeated measurement diastolic blood pressure &lt; 55 &gt; = 90 mmHg screen supine position 4 . Repeated measurement pulse rate &lt; 40 bpm &gt; 90 bpm screen 5 . Any laboratory value outside reference range investigator considers clinical relevance 6 . Any evidence concomitant disease judge clinically relevant investigator 7 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 8 . Surgery gastrointestinal tract could interfere kinetics trial drug 9 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder 10 . History relevant orthostatic hypotension , faint spell , blackouts 11 . Chronic relevant acute infection 12 . Positive test infectious disease 13 . History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) 14 . Intake drug long halflife ( &gt; 24 hour ) within 30 day less 10 halflives respective drug prior administration trial medication 15 . Within 10 day prior administration trial medication , use drug might reasonably influence result trial 16 . Participation another trial investigational drug administration within 60 day prior administration trial medication 17 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 18 . Inability refrain smoke trial day 19 . Alcohol abuse ( consumption 40 g per day ) 20 . Drug abuse 21 . Positive test alcohol breath test drug screen test 22 . Blood donation ( 100 mL within 30 day prior administration trial medication trial ) 23 . Intention perform excessive physical activity within one week prior administration trial medication trial 24 . Inability comply dietary regimen trial site 25 . At screening , mark baseline prolongation QT/QTc interval ( repeat demonstration QTcF interval &gt; 450 m ) relevant ECG find 26 . A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) 27 . Abnormal parameter thyroid hormone ( T3 , T4 , TSH ) , coagulation parameter ( partial thromboplastin time ( aPTT ) , prothrombin time ( PT ) fibrinogen ( retests prior inclusion allow ) ) 28 . Subject assessed investigator unsuitable inclusion , instance , consider able understand comply study requirement , condition would allow safe participation study 29 . Male subject agree minimize risk female partner become pregnant first dose day two month trial completion . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive least two month prior trial participation ) 30 . History retinopathy 31 . Any history present disease central nervous system , spinal cord spinal column , could provoke complication procedure lumbar catheterization/intrathecal punction 32 . Signs intracranial overpressure determine funduscopy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>